Skip to main content

Deal Structure Trade Space

Most BD conversations anchor on licensing because that’s the default. But the same asset could be 20–60% more valuable under a different structure — or significantly less. Below are four representative assets run through all five deal structures, ranked by total value to the licensor.

Computed by optimizeDealStructure() (backtest-validated engine). Upfront, milestone allocation, and royalty structures vary by deal type per the DEAL_TYPE_CAPTURE and PHASE_ALLOCATION tables. All figures in $M unless noted otherwise.

Phase 2 oncology mAb

NSCLC, $2B peak, small-biotech licensor

TA: oncologyPhase: phase2Modality: mabPeak: $2000M
Recommendation (moderate)

Your asset would be worth 31% more as a Acquisition (M&A) ($489M) than as Licensing ($374M). Based on phase2 oncology benchmarks and your licensor profile, this structure better matches the asset's stage and the typical buyer behavior in this space.

Recommended

Acquisition

#1

Cash now for full ownership. Highest upfront ratio.

Upfront$489M
Total deal$489M
vs current+0%

Top-ranked: Acquisition (M&A) delivers $489M total deal value with $489M upfront (100% upfront ratio). Best fit for the licensor's risk and cash preferences.

Collaboration

#2

Research funding + joint milestones. Early-stage partnership.

Upfront$97M
Total deal$557M
vs current+0%

Research Collaboration: $557M total (17% upfront) — 49% better than your selection.

Co-development

#3

Shared R&D cost, shared upside. Lower upfront, higher retained NPV.

Upfront$101M
Total deal$449M
vs current+0%

Co-development: $449M total (22% upfront) — 20% better than your selection.

Licensing

#4

Upfront + milestones + royalties. Standard bio-pharma template.

Upfront$150M
Total deal$374M
vs current+0%

Licensing: $374M total — comparable to your selection (within 20%).

Option

#5

Small option fee now + larger exercise fee after data. Probability-weighted.

Upfront$26M
Total deal$259M
vs current-0%

Option / License: $259M total — 31% lower than your selection.

Phase 3 rare disease gene therapy

DMD, $1B peak, orphan designation

TA: rareDiseasePhase: phase3Modality: geneTherapyPeak: $1000M
Recommended

Acquisition

#1

Cash now for full ownership. Highest upfront ratio.

Upfront$671M
Total deal$671M
vs current+0%

Top-ranked: Acquisition (M&A) delivers $671M total deal value with $671M upfront (100% upfront ratio). Best fit for the licensor's risk and cash preferences.

Licensing

#2

Upfront + milestones + royalties. Standard bio-pharma template.

Upfront$212M
Total deal$570M
vs current+0%

Licensing: $570M total — comparable to your selection (within 20%).

Co-development

#3

Shared R&D cost, shared upside. Lower upfront, higher retained NPV.

Upfront$147M
Total deal$653M
vs current+0%

Co-development: $653M total — comparable to your selection (within 20%).

Collaboration

#4

Research funding + joint milestones. Early-stage partnership.

Upfront$104M
Total deal$593M
vs current+0%

Research Collaboration: $593M total — comparable to your selection (within 20%).

Option

#5

Small option fee now + larger exercise fee after data. Probability-weighted.

Upfront$34M
Total deal$344M
vs current-0%

Option / License: $344M total — 40% lower than your selection.

Phase 2 immunology bispecific

Atopic dermatitis, $1.5B peak, mid-biotech licensor

TA: immunologyPhase: phase2Modality: bispecificPeak: $1500M
Recommendation (moderate)

Your asset would be worth 32% more as a Acquisition (M&A) ($178M) than as Licensing ($135M). Based on phase2 immunology benchmarks and your licensor profile, this structure better matches the asset's stage and the typical buyer behavior in this space.

Recommended

Acquisition

#1

Cash now for full ownership. Highest upfront ratio.

Upfront$178M
Total deal$178M
vs current+0%

Top-ranked: Acquisition (M&A) delivers $178M total deal value with $178M upfront (100% upfront ratio). Best fit for the licensor's risk and cash preferences.

Collaboration

#2

Research funding + joint milestones. Early-stage partnership.

Upfront$34M
Total deal$196M
vs current+0%

Research Collaboration: $196M total (17% upfront) — 45% better than your selection.

Co-development

#3

Shared R&D cost, shared upside. Lower upfront, higher retained NPV.

Upfront$40M
Total deal$176M
vs current+0%

Co-development: $176M total (23% upfront) — 30% better than your selection.

Licensing

#4

Upfront + milestones + royalties. Standard bio-pharma template.

Upfront$54M
Total deal$135M
vs current+0%

Licensing: $135M total — comparable to your selection (within 20%).

Option

#5

Small option fee now + larger exercise fee after data. Probability-weighted.

Upfront$9M
Total deal$93M
vs current-0%

Option / License: $93M total — 31% lower than your selection.

Phase 1 platform RNAi

Cardiovascular, $800M peak, early-stage option play

TA: cardiovascularPhase: phase1Modality: rnaiPeak: $800M
Recommended

Co-development

#1

Shared R&D cost, shared upside. Lower upfront, higher retained NPV.

Upfront$31M
Total deal$139M
vs current+0%

Top-ranked: Co-development delivers $139M total deal value with $31M upfront (22% upfront ratio). Best fit for the licensor's risk and cash preferences.

Option

#2

Small option fee now + larger exercise fee after data. Probability-weighted.

Upfront$9M
Total deal$88M
vs current+0%

Option / License: $88M total — comparable to your selection (within 20%).

Collaboration

#3

Research funding + joint milestones. Early-stage partnership.

Upfront$10M
Total deal$57M
vs current+0%

Research Collaboration: $57M total — comparable to your selection (within 20%).

Licensing

#4

Upfront + milestones + royalties. Standard bio-pharma template.

Upfront$-80M
Total deal$-80M
vs current+0%

Licensing: $-80M total — comparable to your selection (within 20%).

Acquisition

#5

Cash now for full ownership. Highest upfront ratio.

Upfront$-169M
Total deal$-82M
vs current+0%

Acquisition (M&A): $-82M total — comparable to your selection (within 20%).

How we compute this

For each asset, the engine runs calculateRNPV() five times — one per deal type. Peak sales, PoS, discount rate, and cash flow timing are constant across runs; only deal-type-specific upfront / milestone / royalty structure varies. The resulting implied deal values are the headline numbers shown in each card.

Rankings apply a licensor preference profile: clinical-stage biotechs with short cash runway weight cash-now higher, large pharma weights retained upside higher. The profile shifts ties but doesn’t override a meaningfully better headline value.

We surface a recommendation only when the top alternative beats the user’s current structure by ≥20%. Below that threshold, the signal is too weak to override the strategic context (tax, IP, control, relationship dynamics) that drive the choice in practice. This tool informs the conversation; it doesn’t replace it.

Deal Structure Trade Space | Ambrosia Benchmarker | Ambrosia Ventures